CLEVELAND BIOLABS INC CBLI Cash Flow

Cleveland biolabs inc (CBLI)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss
-601	-1,168	-467	-633	-893	-448	-1,128	-872	-1,258	-1,198	-1,296	-5,648	-1,700	-1,173	1,140	-1,886	-670	-1,668	-3,215	-4,461	-3,698	10,683	-4,615	-4,131	-1,901	-844	-4,610	-3,886	-10,787	2,206	-12,315	-5,906	-6,398	-7,735	-2,878	11,130	-5,745
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
3	3	2	3	3	4	4	4	4	-	5	5	5	-	12	14	26	-	116	60	65	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash investment income
-	-	-	-	-	0	7	10	11	-	13	14	14	-	11	10	9	-	6	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	57	91	94	94	94	102	119	130	127	187	114	106	103
Amortization of loan costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91	-	-	-	-	-	-	-	-	0	0	6	6
Unrealized currency gain on short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	86	-126	526	-539	-	-	-	-
Gain on equipment disposal
-	6	6	38	-1	0	0	0	35	0	0	0	6	180	0	0	0	-	-	-	-	0	0	0	-24	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	0	-0	2	11	-19	75	6	33	243	70	134	48	-118	469	487	635	263	1,049	656	565	981	955	1,184	923
Warrant issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	617	0	0	0	171	-	-	-	-	-	-	-	-	-	-	-	-
Equity in loss of Incuron, LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-114	-247	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in value of warrant liability
160	-18	-36	-112	94	-162	-121	-170	-508	14	166	4,124	121	-399	-1,834	547	-1,412	-1,260	-46	1,480	49	-998	836	-412	-2,087	-2,353	-1,163	-2,795	3,447	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Warrant issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-301	119	31
Change in value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,719	-	-3,993	-17,815	714
Accounts receivable and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-41	-148	-590	720	435	-40	5	-700	-1,001	1,328	-10,211	2,112	3,129
Other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	54	-245	-148	-377	74	-	-	-	-	-	-	-	-
Accounts receivable and other current assets
-8	145	-134	26	30	51	-163	-155	-163	-	44	-25	102	-	514	-211	554	-	557	-210	113	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-58	609	-115	-65	-269	-153	364
Other long-term assets
-	-0	-0	-12	0	-3	-0	4	-1	0	0	0	0	-	-	-	-	0	-4	-4	-3	3	-3	-6	-9	25	-12	-5	22	3	-0	-2	4	0	-15	0	15
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-273	-403	11	-35	-286	1,081	-237	-387	153	-414	680	-626	11
Accounts payable and accrued expenses
4	971	-339	36	-3	-516	-69	-183	444	-	-250	-72	-621	-	-51	-611	268	-	115	-416	311	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	825	-	-	-	-
Net cash used in operating activities
-425	-	-	-	-827	-	-	-	-1,199	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-7,003	-	-3,285	-7,375	-4,794	-6,295	-5,538	-4,228	-842
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-0	-139	43	83	-267	-373	256	254	-168	-417	-278	108	-959	-440	-442	-219	-	-	-	-	0	-2,308	-4	-4
Accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	929	-344	87	-206	643	-	-	-	-	-	-	-	-330
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-1,279	-1,432	-1,580	-2,318	265	-1,357	-1,690	-2,256	-3,220	-3,886	-2,745	-2,227	-3,138	-3,590	-4,892	-2,833	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from investing activities:
Purchase of short-term investments
-	-	-	-	-	941	2,646	2,203	1,945	2,497	1,538	675	3,919	4,418	3,994	8,813	0	-48	16,137	60	723	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of short-term investments
-	-	-	-	-	1,353	4,196	2,715	3,429	3,422	3,632	2,360	3,100	6,967	4,087	5,323	6,335	2,425	410	348	0	-	-	-	-	-16	-42	941	1,315	-	-	-	-	-	-	-	-
Sale of short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,442
Purchase of equipment
-	-	-	-	-	6	2	-0	19	4	0	0	0	-	-	-	-	3	3	9	3	7	1	-0	10	14	39	65	20	23	38	34	81	147	239	101	167
Proceeds from sale of equipment
-	-	-	-	-	0	0	0	35	0	-0	0	8	182	0	1	15	25	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment in patents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-0	202	120
Net cash provided by investing activities
-	-	-	-	-	-	-	-	1,501	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,295	-	2,250	-3,661	-81	-5,344	82	925	-1,730
Cash flows from financing activities:
Decrease in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	64	770	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	920	2,093	1,684	-810	2,728	87	-3,492	6,350	2,515	-15,178	2,342	43	-644	-1,417	285	-10	-	-	-	-	-	-	-	-	-	-	-	-
Exercise of warrants
382	-	-	-	-	0	0	0	55	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	891
Issuance of common stock, net of offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	24,141	-452	3,501	0	0	3,342	6,355	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of long-term debt and capital leases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,005	186	189	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncontrolling interest capital contribution to Incuron, LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2,340
Exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	539	417	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Exercise of options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	4	214	307
Exercise of options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-
Repayment of capital lease obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19	19	18	23	16	16	15	15	4	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	0	55	0	0	0	0	0	0	0	539	126	22,136	-638	3,311	-198	2,215	2,237	6,335	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate change on cash and equivalents
-	-	-	-	-	-	-	-	-0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	355	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
382	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-16	-	-15	5,878	-3	9,005	4	22,251	3,508
Effect of exchange rate change on cash and equivalents
-23	4	-5	6	9	-	-	-	-	-0	-1	7	47	-144	-89	1	42	133	101	-24	24	-792	-433	81	-147	10	91	-267	-157	133	9	276	118	247	-284	29	164
Decrease in cash and cash equivalents
-67	-361	-750	-561	-818	-	-	-	-	-360	658	111	-3,081	2,849	-1,360	-5,182	4,676	-444	3,172	-1,065	1,152	-4,773	-3,226	-2,288	3,343	-4,264	1,067	-6,523	-5,883	13,463	-1,041	-4,881	-4,761	-2,387	-5,736	18,977	1,100
Supplemental disclosure of cash flow information:
Cash paid during the period for interest
-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	290	135	43	47	35	54	200	159	0	4	6	5	6	7	7	2	-	-	-	-
Conversion of warrant liability to equity upon warrant exercise
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	47	947
Cashless exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	50	-	-	-	-	-	-	-	-	-	-	-	-
Noncash warrant issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	15	-	-	-	-	-	-	-	-	-	-	-	-
Equipment acquired through lease financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	221	-	-	-	-